Revelation Biosciences, Inc. (REVB) · Nov 5, 2026 · Earnings

Revelation Biosciences earnings beat as AKI trial setup advances

Beat — GAAP EPS ($5.92) vs approximately ($6.16) consensus

Revelation Biosciences earnings narrowly beat estimates while the company advances its AKI trial setup and stretches cash into Q2 2027.

Revelation is a clinical-stage biotech building Gemini toward a planned Phase 2/3 acute-kidney-injury study, after agreeing with the FDA on a roughly 300-patient adaptive pathway; its 2026 work has focused on assembling the trial infrastructure rather than producing clinical data.

The quarter modestly cleared the earnings bar. Reported GAAP loss per share was $5.92 versus a published consensus of approximately $6.16, a narrow beat; there is no revenue to assess because Revelation remains pre-commercial. The lower per-share loss is also influenced by a much larger share base than last year, so it is not evidence of improving underlying economics.

Q3 2026Q3 2025Consensus
Net loss (Results of Operations)$3.3M$1.9M
Loss per share (Results of Operations)($5.92)($49.51)($6.16)
Operating cash burn (Results of Operations)$2.6M$1.6M
Cash balance (Balance Sheet)$9.1M$10.7M at Dec. 31, 2025

Operational progress is real but still preparatory. Selecting a global CRO moves GEM-AKI closer to execution, but it is a setup milestone rather than a study start, enrollment update, or efficacy readout. 〔0〕

Liquidity looks less immediately constrained, though financing risk remains. Management now says the $9.1 million cash balance should fund operations into the second quarter of 2027, while the June 2026 filing had warned that cash would not sustain operations for a year and raised substantial doubt about going concern. The caveat is that quarterly operating cash use rose to $2.6 million from $1.6 million, and the company still has no product revenue; the runway therefore depends on current spending assumptions holding. 〔1〕

The $94 billion market estimate adds narrative, not validation. It may support the commercial opportunity management is presenting, but this filing supplies no new human efficacy, safety, enrollment, or regulatory evidence for Gemini.

Bottom line: This is a small step forward: a narrow earnings beat, a CRO selected, and a stated cash runway into Q2 2027. The business story improves slightly, but the company remains an unproven, cash-burning biotech still waiting for the AKI study to begin and generate meaningful clinical evidence.

What to watch next

GEM-AKI study initiation update, targeted for Q4 2026

Original filing on SEC EDGAR

Revelation Biosciences earnings beat as AKI trial setup advances | REVB Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.